Summary of Conference Call for New Jie Wei Zhuang Company Overview - **Company**: New Jie Wei Zhuang - **Industry**: PCB (Printed Circuit Board) Equipment Manufacturing Key Points and Arguments Financial Performance - In the first half of 2025, New Jie Wei Zhuang achieved total revenue of 654 million yuan, a year-on-year increase of 46% [3] - Operating profit reached 132 million yuan, nearing 90% of last year's total of 160 million yuan [3] - Comprehensive gross margin exceeded 40%, and net profit margin surpassed 21%, significantly up from over 30% last year [4] Product Line Performance - TCB (Thermal Compression Bonding) product line accounted for approximately 70% of revenue [4] - Semiconductor business revenue was about 130 million yuan, showing substantial growth compared to the previous year [4] - Maintenance service revenue was around 30-40 million yuan [4] Market Position - New Jie Wei Zhuang became the global leader in the PCB exposure machine market in 2024, holding a market share of about 15-16% [5][6] - Cumulative shipments exceeded 2,500 units, with over 280 units delivered to Southeast Asia [6] Capacity Expansion - Phase II capacity deployment has commenced, with expectations to fully ramp up by Q4 2025, achieving a monthly delivery of around 100 units [7] - Initial design capacity for Phase I was 500 units per year, with Phase II planned for 1,000 units, totaling 1,500 units [10] Customer Demand and Orders - Major customers like Dongshan and Pengding are expected to gradually realize their expansion plans in 2026, which will accelerate New Jie Wei Zhuang's order and delivery pace [13] - Anticipated orders in the PCB substrate field for the second half of 2025 are expected to exceed 20-30 units, with high-end product prices reaching 5-6 million yuan [14] Future Outlook - The company submitted its Hong Kong stock application on March 1, 2025, aiming to raise funds for R&D, capacity expansion, global sales, and customer service network development, with funds expected to be in place by Q1 2026 [29] - The company is also developing CO2 laser drilling equipment, with 10 units ordered this year, targeting to fill the market gap left by Mitsubishi's insufficient capacity [20] Challenges and Considerations - The company faces challenges in meeting large volume orders due to a lack of experience in bulk delivery, which may affect production schedules [21] - The expected increase in demand for laser drilling equipment in 2026 may not be fully met by domestic manufacturers due to capacity constraints [22] Pricing and Market Trends - The price of inner substrate equipment ranges from 3 million to 5 million yuan, while high-precision narrow board equipment can reach 20 million to 30 million yuan [30] - The average price of single equipment is expected to increase by about 10% in 2026 due to rising demand for high-end processes [33] Strategic Planning - The company plans to enhance production capacity through overtime and has a clear financing strategy to support its growth initiatives [29] - Future production and sales planning will be finalized around October 2025, based on market research and customer investment plans [28] Additional Important Information - The company has established formal partnerships with over 70 of the top 100 PCB companies globally, laying a solid foundation for future bulk orders [13] - The company is optimistic about long-term business planning despite limited revenue contributions in 2025 [31] - In the mask plate field, the company is currently producing equipment for 90-130 nm processes and aims to enhance its technology to 45-60 nm for mass production [32]

Summary of Dongwei Technology Conference Call Company Overview - **Company**: Dongwei Technology - **Industry**: PCB (Printed Circuit Board) Equipment Manufacturing Key Financial Highlights - **Q2 Revenue**: 232 million RMB, up 19.14% YoY [2] - **Net Profit**: 25.5 million RMB, up 3.23% YoY, and up 49.93% QoQ [2] - **H1 2025 Revenue**: 443 million RMB, up 13.07% YoY [3] - **H1 2025 Net Profit**: 42.5 million RMB, down 23.66% YoY due to lack of high-margin new energy product revenue and rising raw material costs [3] Product Development and Market Demand - **Vertical Continuous Plating Equipment**: Orders increased over 100% YoY, significantly contributing to revenue growth [2][3] - **Three-in-One HDI Advanced Products**: Approximately 10 units deployed, with expected order increases in H2 and significant growth in 2026 [2][6] - **Horizontal Three-in-One Plating Equipment**: Addresses issues of chemical binding in sales, offers broader applicability, and superior plating uniformity compared to German products [2][8] - **Global Demand for Horizontal Three-in-One Equipment**: Estimated annual demand between 500 million to 1 billion RMB, with a gross margin of 40%-45% [9] Technological Advancements - **Pulse VCP Technology**: Enhances copper thickening in deep holes, accounting for 60% of sales with a gross margin of about 40% [10] - **Comparison of Plating Technologies**: Pulse VCP is suitable for high-aspect-ratio boards, while horizontal three-in-one is for HDI boards [10][11] Market Trends and Competitive Landscape - **Increased Overseas Orders**: Now 20%-30% of total orders, primarily from South Korea, Japan, Europe, and Southeast Asia [5][15] - **Challenges for New Entrants**: Significant technical and time challenges exist for companies attempting to enter the plating equipment market [16] Profitability and Pricing Strategy - **Profit Margin Trends**: Expected to increase due to selective order acceptance and higher export orders with better margins [14][26] - **PCB Order Situation**: Orders are full, with some capacity constraints, but no immediate price increases anticipated [25] Future Outlook - **Market Expansion**: Plans for a technology service center in Thailand to enhance international market presence [5][15] - **R&D Expectations**: Anticipated improvements in market performance and R&D outcomes over the next one to two years [28] Additional Insights - **Customer Validation**: Ongoing collaborations with solid-state battery manufacturers and positive feedback on new products [19][21] - **Production Capacity**: Current orders sufficient for 3-4 months of production, with no immediate need for overtime [25][27] This summary encapsulates the key points from the conference call, highlighting the company's financial performance, product developments, market trends, and future outlook.

Summary of Shandong Road and Bridge Conference Call Company Overview - **Company**: Shandong Road and Bridge - **Industry**: Infrastructure and Construction Key Financial Metrics - **Net Profit**: 1H 2025 net profit was 1.284 billion yuan, a decrease of 1.17% year-on-year, while net profit attributable to the parent company increased by 0.89% to 1.029 billion yuan [2][3] - **Operating Revenue**: 1H 2025 operating revenue reached 28.575 billion yuan, a year-on-year increase of 0.26% [3] - **Operating Cash Flow**: Negative operating cash flow of 1.723 billion yuan, but improved by 33.79% year-on-year [2][3] - **Total Assets**: As of June 30, 2025, total assets were 169.39 billion yuan, up 3.69% from the beginning of the year [3] - **Total Liabilities**: Total liabilities were 132.558 billion yuan, up 3.58% from the beginning of the year [3] - **Equity**: Equity attributable to shareholders was 25.126 billion yuan, up 3.38% from the beginning of the year [3] Order and Market Performance - **Total Bids**: In 1H 2025, the company secured bids worth 48.73 billion yuan across 15 sectors, including road and bridge, housing construction, and municipal engineering [2][5] - **Geographical Distribution**: 36.7% of bids were from outside the province, 43.9% from within the province, and 19% from overseas [5] - **Overseas Orders**: The company achieved 9 billion yuan in overseas orders in 1H 2025, with a target of over 10 billion yuan for the full year [10][13] Strategic Initiatives - **International Expansion**: The company is enhancing its overseas contracting capabilities, focusing on countries along the "Belt and Road" initiative, particularly in Africa and Eastern Europe, while also exploring South America and Central Asia [6][14] - **Risk Management**: Measures such as risk classification of projects and strict bidding controls are in place to protect interests amid improving funding conditions for urban investment platforms [7] Future Outlook - **Cash Flow Improvement**: The company expects cash flow to continue improving in the second half of 2025, with a peak in investment recovery anticipated in 2026 [9][12] - **Investment Management**: The company aims to balance annual investment recovery to avoid concentrated pressure and manage cash flow effectively [10][12] - **Government Support**: The company is optimistic about government support for infrastructure projects, with expectations of continued growth in the "14th Five-Year Plan" period [18][19] Competitive Landscape - **Market Position**: The company does not perceive aggressive competition from state-owned enterprises in Shandong, as some have retreated from certain sectors [20] - **Local Market Dynamics**: There is a trend towards a unified national market, reducing local protectionism, which allows the company to compete effectively across various provinces [21][22] Profitability Expectations - **Profit Margins**: The company maintains a profit level above 10%, with expectations for revenue and profit growth around 3.5% for the year [23][24] PPP Projects - **Policy Impact**: Recent policy changes are expected to positively influence the collection side of PPP projects, although tangible progress is yet to be seen [25] Conclusion - **Long-term Growth**: The company is positioned for sustainable growth, leveraging its extensive experience and market strategies to enhance shareholder value and maintain a strong competitive edge in the infrastructure sector [30][31]

Summary of Osai Kang's Conference Call Company Overview - **Company**: Osai Kang - **Industry**: Pharmaceutical, focusing on innovative and generic drugs Key Points and Arguments Financial Performance - In the first half of 2025, Osai Kang achieved revenue of 1.007 billion yuan, a year-on-year increase of 9.2% [3] - Net profit attributable to shareholders was 160 million yuan, up 112% year-on-year [3] - R&D investment was 202 million yuan, accounting for 20.03% of revenue [3] - The company expects a revenue growth rate of approximately 10% for the full year, with profit growth expected to exceed revenue growth [4] Product Development and Pipeline - **Key Products**: - **Liatinib (Aoyi Xin)**: Approved for first-line indications, with median PFS of 20.7 months; clinical data published in *The Lancet* [2] - **ASKC 202C MET Inhibitor**: Phase III clinical research initiated; Phase I ORR reached 62.5% [2] - **ASKB 589 Claudin 18.2 Monoclonal Antibody**: Phase III clinical trial ongoing; ORR for high-expression patients at 81.8% [2] - **ASKC 109**: New oral iron supplement expected to submit NBA application this quarter [2] - **ASKG712**: Dual-target ophthalmic drug for AMD, Phase 2A completed, Phase 2B expected to start by year-end [4] R&D Strategy - The company maintains a high R&D investment ratio to enhance core competitiveness [3] - R&D expenses were reduced due to capitalizing certain R&D investments [3] - Plans to launch at least one innovative drug annually over the next three years [4] Market Dynamics - The generic drug segment contributed significantly to sales, with over 1 billion yuan in sales in the first half of 2025, reflecting a growth rate of 9.9% despite market challenges [13] - The oncology product line saw over 15% growth, while chronic disease products grew by 20% [13] Collaborations and Partnerships - Osai Kang has engaged in collaborations for early-stage drug development, including partnerships with Shanghai Institute of Materia Medica and Yaoming Kangde [16] - The company is actively seeking external business development opportunities for overseas licensing of products like Claudin 18.2 and CMET inhibitors [30] Future Outlook - The company aims to maintain steady revenue growth and is confident in achieving a stable growth rate in 2026 [30] - Plans to introduce 1 to 2 new pipelines in the second half of the year to ensure continuous innovation [30] Additional Insights - The company is exploring the potential of TCE technology and its application in clinical settings [22] - Osai Kang's unique peptide shielding technology has shown significant advantages in safety and efficacy compared to competitors [11] Conclusion Osai Kang is positioned for growth with a robust pipeline of innovative drugs, strong financial performance, and strategic collaborations. The company is focused on maintaining its competitive edge through high R&D investment and exploring new market opportunities.

Summary of the Conference Call for Oppein Home Company Overview - **Company**: Oppein Home - **Industry**: Home Furnishing Key Points and Arguments Financial Performance - In the first half of 2025, Oppein Home reported revenue of **8.24 billion** yuan, a **4% year-on-year decline**, while net profit attributable to shareholders was **1.02 billion** yuan, reflecting a **2.9% increase** in profitability [2][4][11] - The second quarter showed a narrowing revenue decline of **3.4%**, indicating improved operational conditions [2][4] - Gross margin increased to **36.24%**, up **3.67 percentage points**, and net margin rose to **12.36%**, up **0.82 percentage points**, due to lower material costs and operational efficiencies [2][4][8] Market Environment - The home furnishing market faced challenges, with national statistics showing declines in real estate investment, completion, and sales [4] - The furniture manufacturing sector saw a **4.9%** drop in revenue among major companies, with profits down **23.1%** [4] - Oppein Home's revenue from distribution channels fell **4%**, while direct sales and foreign trade channels grew by **5.6%** and **30%**, respectively [2][4] Strategic Initiatives - The company implemented performance assessment reforms and supply chain improvements to enhance operational quality despite market pressures [2][6] - Oppein Home is focusing on diversifying its revenue streams and optimizing cost structures through its "one-stop shopping" model, which encourages customers to purchase multiple product categories [13][20] - The introduction of top industry talent and a "land distribution" management model aims to boost the autonomy of various business units and foster internal competition [3][15][28] Government Policies and Consumer Behavior - National subsidy policies have stimulated consumption but have not fully reversed the downward revenue trend [10][11] - The company expects future subsidy policies to focus on stabilizing consumption and promoting industrial upgrades, but these may not be sufficient to drive revenue growth alone [11] Future Outlook - The company anticipates continued pressure on gross and net margins due to external market conditions and increased competition [9][18] - Oppein Home is exploring opportunities in the renovation of existing homes, which is becoming a significant growth area as new home sales slow [20][21] - The company plans to enhance its product offerings and service efficiency to capture the potential in the renovation market [21][26] Challenges and Adaptations - The company is aware of the competitive landscape within the furniture industry, with a trend towards market share concentration [19] - Oppein Home is adapting by enhancing its digital tools and optimizing its business layout to improve operational efficiency [19][22] Conclusion - Oppein Home is navigating a challenging market environment through strategic reforms, operational improvements, and a focus on diversifying its revenue streams. The company remains cautiously optimistic about its future performance while preparing for ongoing market challenges [30]

Summary of Huada Technology Conference Call Company Overview - **Company**: Huada Technology - **Industry**: Automotive manufacturing and metal processing Key Points Financial Performance - **Revenue Forecast**: Expected annual revenue between 5.8 billion to 7 billion CNY, with profits ranging from 439 million to 565 million CNY, indicating a rebound in performance [2][3] - **Q2 Performance**: In the first half of 2025, revenue reached 2.87 billion CNY, a year-on-year increase of 22.48%, with net profit close to 200 million CNY, up 21.17% [3] Business Segments - **Core Business Areas**: - Body stamping parts (traditional core business) - Battery box housings (acquisition of Jiangsu Hengyi) - Die-casting business (Huachi New Energy) [2][4] - **Client Base Expansion**: New clients include Geely, Chery, Great Wall, Xiaomi, and Li Auto, with total designated contracts nearing 10 billion CNY [2][6] Cost Management - **Sales and Management Expenses**: Sales expenses increased due to new product development and client transitions, while management expenses remained stable, showcasing strong cost control capabilities [2][7] Market Trends and Adaptation - **Electric Vehicle Market**: The company is actively transforming to adapt to electrification trends, significantly increasing new product development projects [6] - **Emerging Opportunities**: Focus on new demands such as flying cars and humanoid robots, with multiple mass production projects in reserve [8] Profitability and Margins - **Gross Margin Improvement**: Q2 gross margin increased by 2-3 percentage points due to stable main business profit margins, expanded scale of Hengyi, and manageable depreciation from new projects [9][10] Future Growth Projections - **Revenue Growth Expectations**: Anticipated continued revenue growth in the second half of 2025, driven by new client projects from both traditional and emerging brands [11] - **Investment in Chery**: Investment of 416 million CNY in Chery, with expected returns contingent on Chery's market performance post-IPO [5][17] Strategic Partnerships - **Collaboration with SAIC Group**: Close cooperation supplying various components, enhancing market competitiveness [12] Industry Positioning - **Market Share Dynamics**: Shift in market share from joint ventures to domestic brands, with a focus on consolidating the industry [15] - **Long-term Strategy**: Plans to integrate and consolidate within the industry, similar to leading companies like Fuyao Glass [15] Capital and Investment Strategy - **Financial Health**: The company maintains a low debt ratio and good cash reserves, allowing for flexible financing options [18] Overall Outlook - **Performance Goals**: The company’s three business segments are expected to perform well, with revenue projections for 2025 and 2026 indicating significant growth compared to previous years [19][20]

Summary of Huatai Medical Conference Call Company Overview - Huatai Medical has developed four main business segments: electrophysiology, coronary access, peripheral vascular intervention, and non-vascular intervention, covering both devices and consumables, with a notable advantage in electrophysiology through PFA technology [2][3][4] Core Insights and Arguments - The electrophysiology market is expected to grow steadily due to a large patient base suffering from arrhythmias and the introduction of new technologies like PFA. The aging population is likely to increase surgical volumes, although there are concerns regarding medical insurance pressures [2][7][8] - China's penetration rate for cardiac electrophysiology surgeries is significantly lower than that of the U.S., indicating substantial growth potential. Learning from the coronary intervention industry, collective procurement can enhance product accessibility and promote surgical volume growth [2][9] - International consensus is shifting towards prioritizing electrophysiology surgeries as a first-line treatment, which may lead to adjustments in domestic guidelines. Collective procurement and price reductions are expected to improve patient accessibility and increase the supply of medical resources, driving market development [2][11] - The adoption of 3D surgical technology is pushing companies to develop corresponding devices and bind them with consumables. Huatai Medical has significantly improved its 3D device performance with support from Mindray, positioning itself advantageously in the PFA technology sector [2][12] Financial Performance - Huatai Medical's revenue and profit are projected to grow rapidly, with expected revenue of 2.066 billion yuan and a net profit of 673 million yuan in 2024, maintaining an approximate 30% growth rate in the coming years. The gross margins of various business segments are steadily increasing, indicating a positive long-term outlook [3][30] Business Development and History - Established in 2002, Huatai Medical initially focused on electrophysiology and has since expanded into coronary and peripheral interventions. The company went public in 2021 and has seen consistent revenue and profit growth since then [4][30] Market Dynamics - The electrophysiology industry is primarily aimed at treating arrhythmias through catheter ablation or PFA, with a significant patient base of over 27 million in China. This presents a vast development space for the industry [7][8] - The market is expected to grow at a steady rate of 10% to 20% despite pressures from medical insurance, with an estimated surgical volume of around 300,000 procedures currently [8][9] Competitive Landscape - Prior to 2020, the electrophysiology market in China was dominated by foreign companies like Johnson & Johnson and Abbott, holding nearly 80% market share. However, domestic companies like Huatai Medical are gradually gaining ground [15][24] - The collective procurement initiated in 2022 has led to significant price reductions, with average decreases of 30% to 60%, benefiting domestic manufacturers and enhancing their market share [10][22][23] Future Outlook - The electrophysiology industry has a promising future, with significant room for growth compared to domestic coronary surgery penetration rates and surgical volumes in Europe and the U.S. The increasing awareness among patients and improvements in medical supply will further drive surgical volume growth [25][30] - The demand for advanced technologies such as 3D devices and PFA products is expected to rise, with leading companies facing higher technical challenges and market competition [26][27] Strategic Initiatives - Huatai Medical is leveraging collective procurement policies to enhance its capabilities and accelerate growth. The company has successfully replaced foreign brands with domestic products, maintaining steady growth in production and development capabilities [29][30] Conclusion - Huatai Medical is well-positioned for long-term growth in the high-value consumables sector, with a strong focus on innovation and market expansion, particularly in the electrophysiology domain. The company is expected to continue its upward trajectory in revenue and market share, supported by advancements in technology and favorable market conditions [30]

海泰科 摘要 海泰科注塑模具业务营收同比增长 26.3%，改性塑料业务营收同比增长 13.5 倍，但塑料零部件业务营收略有下降，符合预期。新能源汽车相关 订单显著增长 58.8%，显示公司在新能源汽车领域的强劲增长势头。 综合毛利率同比下滑 5 个百分点至 16%，主要原因是价格下滑和新能源 汽车模具价格低于传统燃油车模具价格。新能源汽车模具价格较低是由 于其开发周期短，对供应商反应速度要求高。 泰国工厂持续投资扩产，预计 2026 年达产时，塑料零部件业务年产值 将从目前的 8,000 万元增加到 2 亿至 2.3 亿人民币，显著提升海外业务 贡献。 海泰科积极布局 PEEK 改性材料，计划在合肥建立生产线，并与头部机 器人公司合作开发 PEEK 零部件，主要应用于灵巧手和包覆材料，探索 人形机器人领域的新增长点。 可转债强赎将改善公司财务结构，降低负债水平，提高资本利用效率， 增强财务稳健性。若 9 月 30 日前完成转股，预计每年可节省约 1,000 万元财务费用，对 2025 年净利润产生积极影响。 Q&A 请介绍一下海泰科 2025 年上半年的整体经营情况。 2025 年上半年，海泰科实现营收 3. ...

Summary of Nuo Wei Co., Ltd. Conference Call Company Overview - Nuo Wei Co., Ltd. operates in diverse sectors including oil, gas, water treatment, automation production, and renewable energy, leveraging technological innovation to meet market demands and promote industry diversification [2][3] Financial Performance - In the first half of 2025, Nuo Wei's profit levels remained stable with a gross margin around 35%, a decline from the initial public offering gross margin of 44.41% in 2014, but still considered good within the manufacturing industry [2][5][6] - The company’s net profit has also remained stable [6] Market Trends and Growth Projections - The valve market is projected to grow at a compound annual growth rate (CAGR) of 6% from 2025 to 2033, driven by demand from oil, gas, water treatment, automation production, and renewable energy sectors [2][7] - The company’s strategic direction focuses on high-end, diversified, and global expansion, particularly in downstream sectors like electricity, water treatment, and renewable energy projects [2][8] Order and Market Insights - Order growth in 2025 is primarily from international markets, with domestic orders remaining flat compared to 2024. The Middle East and Asia-Pacific regions show significant growth [9] - Oil and gas extraction, including clean LNG, accounts for approximately 35%-40% of the company’s business, with rapid growth observed in water treatment, nuclear power, and coal chemical sectors [9][10] Nuclear Power Sector - Nuo Wei has experienced rapid growth in the nuclear power sector, expanding its business with China National Nuclear Corporation and increasing its product range, aiming for an annual output value of 600 million yuan [11] Water Treatment Sector - The water treatment industry has shown slight growth, with a healthier customer structure compared to previous years. The company has delivered projects like the data center for Google in Belgium and is engaging with major players like Alibaba and Tencent [12][17] - Expected order size in the water treatment sector for 2025 is around 300 million yuan, maintaining or slightly increasing from 2024 [19] Data Center Business - The outlook for the data center business is optimistic, with participation in significant projects and a focus on meeting the needs of high-quality, low-price-sensitive clients [14][15] - The company anticipates securing data center orders in the Middle East by early next year [15] Strategic Initiatives - Nuo Wei is focusing on high-margin orders in a competitive domestic market and accelerating overseas expansion through standardized product integration [20] - The company is also addressing currency fluctuations that impact overseas margins, maintaining a stable gross margin around 35% [21] Conclusion - Nuo Wei Co., Ltd. is strategically positioned for growth across multiple sectors, with a focus on international markets and high-margin products, while navigating challenges in domestic competition and currency fluctuations.

Summary of Quartz Co. Conference Call Company and Industry Overview - The conference call focuses on Quartz Co., which operates in the semiconductor quartz sand and quartz glass materials industry [2][4] - The global demand for semiconductor-grade quartz sand is approximately 30,000 tons, valued between 3 billion to 4.5 billion RMB [2][6] - Quartz Co. has been certified by major overseas equipment manufacturers, positioning itself as one of the few qualified suppliers globally [2][8] Key Insights and Arguments - The semiconductor quartz materials market is expected to grow at a compound annual growth rate (CAGR) of 10% from 2025 to 2030, potentially reaching a market size of 24 billion RMB by 2030 [2][10] - Quartz Co. aims to increase its market share to 20%, with long-term profit potential estimated at 1.6 billion RMB, corresponding to a market capitalization of approximately 30 billion RMB [2][11] - For 2025, the revenue from semiconductor quartz glass materials is projected to be between 500 million to 600 million RMB, with a net profit margin of 35% to 40%, resulting in an estimated profit of around 200 million RMB [2][11] Competitive Landscape - In the high-temperature diffusion segment, Quartz Co. competes with major players like Mattson and Heraeus, while in the low-temperature etching segment, it competes with six other companies including Mattson and Heraeus [2][4][9] - Currently, only three companies can supply verified semiconductor-grade quartz sand, including Quartz Co., which has recently gained certification [8][9] Market Dynamics - The global market for semiconductor-grade quartz sand is approximately 30 billion to 45 billion RMB, with prices ranging from 100,000 to 150,000 RMB per ton [6][12] - The market for photovoltaic-grade high-purity quartz sand is around 70,000 to 80,000 tons, with Quartz Co. facing challenges due to reduced demand and increased competition [5][14] - The company expects to recover sales in the photovoltaic segment, projecting sales of 30,000 to 40,000 tons by 2030, with profits estimated between 300 million to 600 million RMB [5][14] Future Growth Expectations - The semiconductor quartz sand market is anticipated to grow to 40,000 tons by 2030, with Quartz Co. expected to capture 35% to 40% of this market, translating to revenues of 1.5 billion RMB and net profits of 750 million RMB [3][13] - The company is positioned to fill gaps in the domestic semiconductor supply chain, especially as domestic high-purity silicon sand still relies on imports [18] Additional Considerations - Quartz Co. is involved in multiple business areas, including electric light sources, optical fibers, and optics, which may contribute to its overall valuation [15] - The relationship between Yaoshi Technology and Quartz Co. is noted, as both companies may have synergistic effects in certain business areas [17] - The company’s strong product competitiveness and favorable competitive landscape make it a potential long-term investment opportunity [19]